GLO1 and breast carcinoma: In addition, the Glo1 inhibitor, TLSC702, and the PKCλ inhibitor, aurothiomalate, may serve as novel pharmacological approaches to manage late−stage breast cancer through suppressing both cell viability and tumor−sphere formation in MDA−MB−157 and MDA−MB−468 human basal−like breast cancer cells.